Study Shows Weight Loss Drug Reduces Cardiovascular Risk by 20% in Overweight, Obese Adults
August 11, 2023
A new study shows semaglutide 2.4 mg (Wegovy), a weekly injected prescription medication for overweight adults, may prevent major adverse cardiovascular events (MACEs) such as cardiovascular death, non-fatal heart attack or non-fatal stroke. Novo Nordisk released the results of the significant clinical trial called SELECT. The trail studied the effects...